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Background: The aim of this study was to assess the association between prescription changes frequency (PCF)
and hospital admissions and to compare the PCF to the Chronic Disease Score (CDS). The CDS measures
comorbidity on the basis of the 1-year pharmacy dispensing data. In contrast, the PCF is based on prescription
changes over a 3-month period.
Methods: A retrospective matched case–control design was conducted. 10.000 patients were selected randomly from
the Dutch PHARMO database, who had been hospitalized (index date) between July 1, 1998 and June 30, 2000. The
primary study outcome was the number of prescription changes during several three-month time periods starting 18,
12, 9, 6, and 3 months before the index date. For each hospitalized patient, one nonhospitalized patient was matched
for age, sex, and geographic area, and was assigned the same index date as the corresponding hospitalized patient.
We classified four mutually exclusive types of prescription changes: change in dosage, switch, stop and start.
Results: The study population comprised 8,681 hospitalized patients and an equal number of matched nonhospitalized
patients. The odds ratio of hospital admission increased with an increase in PCF category. At 3 months before the index
date from PCF=1 OR 1.4 [95% CI 1.3-1.5] to PCF= 2–3 OR 2.2 [95% CI 1.9-2.4] and to PCF ≥ 4 OR 4.1 [95% CI 3.1-5.1]. A
higher CDS score was also associated with an increased odds ratio of hospitalization: OR 1.3 (95% CI 1.2-1.4) for CDS
3–4, and OR 3.0 (95% CI 2.7-3.3) for CDS 5 or higher.
Conclusion: The prescription change frequency (PCF) is associated with hospital admission, like the CDS.
Pharmacists and other healthcare workers should be alert when the frequency of prescription changes increases.
Clinical rules could be helpful to make pharmacists and physicians aware of the risk of the number of prescription
changes.
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Medication-related problems are responsible for 3–10%
of acute hospital admissions, of which approximately
half are potentially preventable [1-11]. Hospital admis-
sions can lead to additional functional decline [12,13],
unintentional harm [14], and increased costs. Medica-
tion monitoring and management are methods used to
avoid medication-related complications.* Correspondence: Carolien.sino@hu.nl
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reproduction in any medium, provided the orIn 2008, the Dutch HARM study group established
seven independent risk factors for medication-related hos-
pital admissions: (a) impaired cognition, (b) four or more
diseases in the patient’s medical history, (c) dependent liv-
ing situation, (d) impaired renal function before hos-
pitalization, (e) non-adherence to medication regimen,
(f) the use of five or more medications at the time of
admission (polypharmacy), and (g) age over 65 [11]. In
the industrialized world, the proportion of the popula-
tion that is 65 years or older is rapidly increasing. Elderly
patients more often suffer from multiple morbidities, use
more medications, and are treated by more healthcared. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion is three times higher among people aged 65 years
or older, and four times higher in people aged 75 years
or older, than it is in people younger than 65 years. The
majority of these drugs are taken chronically (www.SFK.nl).
The increased use of prescription drugs by the elderly is a
consequence of their longer lifespan, their increasing use
of health services, and the availability of new drugs [16].
From a clinical perspective, prescription changes are a risk
factor for medication-related hospital admission. During
the course of a disease, it may be necessary to change the
dosage of medication, to switch to a similar medication, to
temporarily withdraw the drug, or to start a new drug.
With the exception of the study of Koecheler [17], who
reported ‘medication regimen changes in four or more
times during the past 12 months’ to be one of the six
prognostic indicators for identifying ambulatory pa-
tients who need pharmacist monitoring, there have
been no other studies that evaluated the association
between the number of prescription changes and hospital
admission. For this reason, we investigated whether the
frequency of prescription changes is associated with
hospital admission, and, if so, whether the strength of
this association changes in the months before hospital
admission.
The Chronic Disease Score (CDS), a well-established
instrument to predict hospital admission, measures co-
morbidity on the basis of the 1-year pharmacy dispensing
data for 17 therapeutic groups of somatic medications
intended for chronic use [18]. The latter makes the CDS a
static instrument. In contrast, the Prescription Changes
Frequency (PCF) is based on prescription changes over a
3-month period.
The objectives of this study were (1) to assess the asso-
ciation between the PCF and hospital admission at dif-
ferent times before admission and (2) to compare the
PCF with the CDS for predicting hospital admission.Table 1 Classification of prescription changes
Classification Definition
1. Change in dosage Change in dosage means that, for the s
25 mg changes in amitryptyline 10 mg
2a. Product formulation switch Metoprolol 50 mg plain tablet instead o
2b. Generic brand switch Change to another product containing
(e.g., atenolol 50 mg tablet (generic pro
tablet (brand) instead of enalapril 10 m
2c. Therapeutic switch Change to another active substance wi
classification are the same (e.g. amitript
instead of citalopram (N06AB04)).
3. Stop No continuation 90 days after one of th
formulation switch (2) ortherapeutic sw
4. Start Start of a drug means prescription of a
and which is not a generic brand substMethods
Study design and setting
This retrospective, matched case–control study used
with permission data from the Dutch PHARMO Record
Linkage System (RLS) (www.pharmo.nl). The PHARMO
RLS includes the dispensing records of community phar-
macies linked to hospital discharge records. It consists
of a representative sample of more than 200 community
pharmacies in more than 50 regions throughout the
Netherlands and is representative for the Netherlands
[19]. It currently includes data for more than 2 million
residents (12% of the Dutch population) regardless of
the type of medical insurance. The computerized phar-
macy dispensing records contain information about
drugs dispensed, dispensing date, prescribing physician,
amount of drug dispensed, and prescribed dosage regi-
men. Patient information includes sex and date of birth.
Each patient is assigned an anonymous unique patient
identification code and each medication is also given a
unique code, according to the Anatomical Therapeutic
Chemical (ATC) classification system. This makes it pos-
sible to track drug therapy and changes in drug therapy
over time. The database does not record the indication
for which a medicine is prescribed and neither does it
include all medications used because non-prescription
products can be purchased over-the-counter.Cases and controls
Initially, 10,000 patients who had been hospitalized for
the first time of possible repeated hospitalizations be-
tween July 1998 and June 2000 were randomly selected
from the PHARMO RLS. The date of hospital admission
was considered the index date. Each hospitalized patient
was matched by age on birthday, sex, geographic area
per pharmacy catchment area with a control patient
who was assigned the same index date. Patients wereame drug, the daily dosage is increased or decreased (e.g., amitriptyline
or vv).
f metoprolol slow release tablet (Selokeen ZOC®).
the same active substance with the same strength and the same dosage
duct) instead of Tenormin® 50 mg tablet (brand) or Renitec® 10 mg
g tablet).
thin the same therapeutic group; the first four characters of the ATC
yline (N06AA09) instead of citalopram (N06AB04) or fluoxetine (N06AB03)
e five control time points and no generic-brand substitution (1), product
itch (3).
drug which had not been prescribed during the previous six months
itution (1), product formulation switch (2) or therapeutic switch (3).
Table 2 Characteristics of hospitalized and non-hospitalized
patients at the index date
Characteristics Hospitalized % Non-Hospitalized %
N=8681 N=8681
Sex
Male 3588 41.3 3588 41.3
Female 5093 58.7 5093 58.7
Age (years at index date)
0 - ≥ 18 574 6.6 574 6.6
>18 - ≥ 45 2737 31.5 2737 31.5
> 45 - ≥ 65 2246 25.9 2246 25.9
> 65 - ≥ 79 2218 25.6 2218 25.6
> 79 906 10.4 906 10.4
Number of medications
0 3416 39.4 4534 52.2
1 1794 20.7 2121 24.4
2 985 11.3 872 10.0
3 767 8.8 535 6.2
4 544 6.3 302 3.5
≥5 1175 13.5 317 3.7
CDS category
CDS score 0 3671 42.3 5206 60.0
CDS score 1-2 1331 15.3 1287 14.3
CDS score 3-4 1731 19.9 1415 16.3
CDS score ≥5 1948 22.4 773 8.9
Duration of hospitalization
1 day 417 4.8
2-5 days 4374 50.4
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24 months before the index date.
Prescription change frequency
A prescription is defined as one medication order. PCF
is defined as the number of prescription changes made
during a 3-month period, without distinguishing be-
tween intentional and unintentional changes. Four dif-
ferent types of prescription changes were distinguished:
(1) change in dosage, (2a) product switch, (2b) generic
brand switch, (2c) therapeutic switch, (3) stopping medi-
cation, and (4) starting medication (Table 1). As we were
interested in whether the PCF affects hospitalization
over time, we calculated the PCF score for both patients
and controls at 18, 12, 9, 6, and 3 months before the
index date. The duration of use of each drug was esti-
mated by dividing the number of dispensed units by the
prescribed daily dose. Drugs that had a theoretical end
date beyond 18, 12, 9, 6, or 3 months before the index
date were considered as being in use on these dates.
Only drugs intended for systemic use were taken into
account. PCF scores were categorized into 0 prescription
changes (PCF 0), 1 prescription change (PCF 1), 2 or 3
prescription changes (PCF 2 or 3), and 4 or more pre-
scription changes (PCF≥ 4).
Chronic disease score
The CDS is calculated on the basis of the use over 1 year
of medications for 17 therapeutic groups of somatic
medications. The CDS has been shown to be a valid
measure of complications related to an individual patient’s
burden of chronic somatic diseases and is clearly associated
with the probability of being hospitalized [20-22]. To
compare the PCF with the CDS, we calculated and
categorized the CDS for the year preceding the index
date into four categories: CDS score = 0, CDS score = 1
or 2, CDS score = 3 or 4, and CDS score 5 or higher.
Statistical analysis
The strength of the association between the PCF score
and hospital admission was calculated by comparing the
number of patients and controls in each PCF category at
18, 12, 9, 6 and 3 months before the index date with
forced entry univariate logistic regression analysis; out-
comes are expressed as the odds ratio (95% CI), using
PCF 0 as reference. To assess the effects of other patient
or hospitalization characteristics, we performed stratified
analyses with age (< 65 years ≥ 65 years), admission type
(emergency or planned), CDS score, and polypharmacy
(the use of five or more drugs concomitantly) as vari-
ables. To assess the strength of the association between
the CDS score and hospital admission, the number of
patients and controls per CDS category were compared
(expressed as OR 95% CI), taking CDS 0 as reference.The nature of prescription changes was determined for
each time period. The correlation between the PCF and
the CDS was measured with a two-tailed Spearman‘s
correlation coefficient. Statistical analyses were performed
using SPSS 16.0 (SPSS, Chicago, IL).
Results
The source population was a random sample of 10,000
patients admitted to a hospital and an equal number of
matched non-admitted individuals (controls). Because
1319 matched patients had less than 24 months of ex-
posure history available in PHARMO RLS, the final
Table 3 The association between prescription change TYPE and hospital admission at different time points before
index date
−18 −12 −9 −6 −3




946 521 1.4 1.3 1.6 1183 699 1.3 1.2 1.4 1093 597 1.4 1.3 1.6 1162 639 1.4 1.3 1.5 1405 656 1.5 1.4 1.6
Product
Switch




114 67 1.7 1.2 2.2 180 93 1.8 1.4 2.3 192 103 1.8 1.4 2.3 219 101 2.1 1.6 2.6 274 91 2.8 2.2 3.5
Therap.
Switch
221 100 1.9 1.5 2.4 230 117 1.7 1.4 2.1 256 96 2.3 1.8 2.9 300 111 2.3 1.8 2.8 345 117 2.6 2.1 3.1
Stop 2735 1923 1.3 1.2 1.3 2961 1910 1.3 1.3 1.4 3122 1950 1.4 1.3 1.4 3122 1943 1.4 1.3 1.4 3102 2005 1.3 1.3 1.4
Start 162 61 2.3 1.7 3.0 136 76 1.6 1.3 2.1 157 61 2.3 1.8 3.1 186 75 2.2 1.7 2.8 227 71 2.9 2.2 3.7
H=hospitalized patients (N=8681), NH=Non=Hospitalized Patients (N=8681), OR=Odds Ratio, CI 95%= Confidence Interval 95%.
PC Type=Prescription Change Type.
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controls. The characteristics of the study population
are displayed in Table 2. The mean age was 52.6
years (SD 21.8) and 58.7% of the participants were women.
At the index date, 60.6% of the patients and 47.8% of the
controls were using systemic medication; the mean number
of drugs used at the index date was 3.0 for patients and 2.1
for controls. In both groups, the number of drugs used
increased with age. The CDS was higher in the patients
than in the controls. The most frequent reasons for pre-
scription changes at all time points before the index date
were stopping medication and changes in dosage (Table 3).
The risk of hospital admission increased with the number
of prescription changes. At 3 months before the index date,
the likelihood of hospitalization increased with increasing
PCF category: the odds ratio (OR) between patients and
controls was 1.4 (95% CI 1.3-1.5) in the lowest PCF cat-
egory (PCF 1) and 4.1 (95% CI 3.1-5.1) in the highest PCF
category (PCF 4). This was also true for comparisons for
18, 12, 9, and 6 months before index date (Tables 4 and 5).Table 4 The association between prescription change frequen
index date
−18 −12 −9
H NH OR CI 95% H NH OR CI 95% H N
PCF Cat
0 6086 6736 1 ref 5844 6524 1 ref 5788 65
1 1631 1418 1.3 1.2 1.4 1731 1564 1.2 1.2 1.3 1720 15
2 or 3 760 451 1.9 1.7 2.1 853 514 1.9 1.7 2.1 899 49
≥ 4 204 76 3.0 2.3 2.4 253 79 3.6 2.8 4.6 274 7
H=hospitalized patients (N=8681), NH=Non=Hospitalized Patients (N=8681).
OR=Odds Ratio, CI 95%= Confidence Interval 95%.
PCF Cat=Prescription Change Frequency Category.The risk of hospital admission also increased per CDS
category. A higher CDS score was associated with an in-
creased risk of hospitalization: OR 1.5 (95% CI 1.4-1.6])
for CDS 1–2, OR 1.7 (95% CI 1.6-1.9) for CDS 3–4, and
OR 3.6 (95% CI 3.3-3.9) for CDS 5 or higher.
Stratification by age (< 65 years ≥ 65 years), admission
type (planned or emergency admission), CDS score, and
polypharmacy resulted in comparable increases in OR
with increasing PCF score. For participants on poly-
pharmacy, the OR of PCF 4 or more decreased between
9 and 3 months before the index date, from 3.5 (95% CI
1.9-6.67) to 2.2 (95% CI 1.0-5.4). When stratified by
CDS, the likelihood of being hospitalized also increased
with increasing PCF score (Figure 1).
A two-tailed Spearman’ correlation coefficient showed
a significant but poor correlation between CDS 0 and
PCI 0 (0.019, p= 0.01) and CDS 5 or higher and PCI 4
or higher (0.027, p=0.01) and no significant correlation
between CDS 1 or 2 and PCF 1 and CDS 3 or 4 and
PCF 2 or 3 at 3 months before the index date.cy and hospital admission at different time points before
−6 −3
H OR CI 95% H NH OR CI 95% H NH OR CI 95%
56 1 ref 5723 6570 1 ref 5591 6537 1 ref
61 1.3 1.2 1.4 1751 1483 1.4 1.3 1.5 5591 1493 1.4 1.3 1.5
0 2.1 1.9 2.3 923 542 2.0 1.8 2.2 1031 560 2.2 1.9 2.4
4 4.2 3.3 5.4 284 86 3.8 3.0 4.8 316 91 4.1 3.1 5.1
Table 5 The association between the chronic disease








0 3671 5206 1 ref
1 or 2 1331 1287 1.04 0.96 1.13
3 or 4 1731 1415 1.27 1.18 1.38
≥ 4 1948 773 2.95 2.71 3.23
OR=Odds Ratio,
CI 95%= Confidence Interval 95%,
CDS =Chronic Disease Score
at indexdate
ref= reference
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The main finding of this study is that the frequency of
prescription changes (PCF) is associated with an in-
creased risk of hospital admission. We also confirmed
the known association between the Chronic Disease
Score (CDS) and hospital admission. While the PCF and
CDS were both associated with hospital admission, the
correlation between the two instruments was poor. The
CDS measures comorbidity on the basis of the 1-year
pharmacy dispensing data. In contrast, the PCF is based
on prescription changes over a 3-month period. The re-
sults showed that the PCF within a three month period
is comparable with the one year period of the CDS.
Therefore, the PCF is more useful in practice.
We found that among patients with a low CDS score,
an increasing number of prescription changes was asso-
ciated with an increased risk of hospital admission.
Stratified analysis of the CDS scores into the four cat-
egories confirmed this finding: at each CDS category, we
found a comparable increase in the risk of hospitaliza-
tion caused by the number of prescription changes.
Stratification by age (<65 or ≥65 year) and medication
use (< 5 or ≥5 medications used) showed an increasing
risk of hospitalization with increasing PCF (Figure 1).
Several studies have reported age and polypharmacy as
risk factors for hospital admission. We found that, based
on PCF scores, even patients younger than 65 years and
patients without polypharmacy were at increased risk of
hospital admission. It is plausible that the risk was lower
for planned than for emergency admissions, but this was
not confirmed after stratification by type of hos-
pitalization. Unexpectedly, patients on polypharmacy
had a decreased risk of hospital admission: PCF 4 or
higher decreased between 9 and 3 months before the
index date. On the basis of this finding, the most com-
mon reason for prescription changes, namely, stopping
medication, would appear to be protective againsthospital admission in patients on polypharmacy. As we
do not know which medications were stopped, this find-
ing does not mean that stopping specific medications is
protective.
The CDS has the disadvantage that it is based on in-
formation about medication history collected for at least
1 year prior to the event under investigation. We showed
that it is possible to predict the risk of hospitalization on
the basis of the number of prescription changes in 3
months. On the other hand, the CDS is based on the use
for 17 therapeutic groups of somatic medications, whereas
the PCF is based on all medications and thus requires
detailed medication histories. The CDS was developed to
measure a patient’s overall health status, but the PCF is
not suitable for this. A potential weakness of the CDS,
which was developed in 1992, is that it has never been ad-
justed to accommodate new medication classes, unlike the
PCF, which is based on all medications used. Despite this,
the CDS is still associated with hospital admissions.
Limitations
This study has a number of limitations. The database
does not provide information about the indication for
which a drug is prescribed, so we cannot comment
about the frequency of medication changes for specific
indications. One could argue that more ill patients will
have more prescription changes. However, this was not
the aim of the study. The use of non-prescription medi-
cines is not known as patients could also buy medica-
tions OTC. In addition, prescribers might not write out
a new prescription each time drug use is changed. Be-
cause the PCF is based on dispensing data from commu-
nity pharmacies, this would mean that the association
between PCF and hospital admission might have been
underestimated. As the data set used in this study cov-
ered the period between July 1998 and June 2000, it is
possible, but unlikely, that since then the prescribing be-
havior of doctors has changed, influenced by medication
reconciliation programmes, or indications for hospital
admission might have become stricter, both of which
would have led to overestimation of the association be-
tween PCF and hospitalization. While the Dutch
PHARMO database is complete, it does not provide in-
formation about the socioeconomic status or compliance
of patients or their health status (the controls might
have been ill less often than the patients); however, as
the controls were sampled independently of exposure
status, these factors would not influence our results.
Lastly, it was outside the scope of this study to distin-
guish between the different reasons for changing medi-
cation in greater detail. To our knowledge, besides the
study of Koecheler et al. [17], no other studies have in-
vestigated prescription changes and the risk of hospital
admission. Several other studies, like the HARM study,
Figure 1 Stratification on age category, admission type, polypharmacy and CDS score.
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admission, but did not focus on prescription changes.
Further research should consider more detailed vari-
ables of the prescription changes like types of medica-
tions involved. In addition, it should be interesting to
test the PCF model in a follow up study.
Conclusion
This longitudinal study of a large group of patients over
24 months demonstrated that the frequency of prescrip-
tion changes (PCF) over a 3-month period is associated
with hospital admission, which suggests that the PCF
could be used as an alternative to the CDS for predicting
hospital admission. In the ambulant setting, the PCF
score could function as a warning signal for an increased
risk of hospitalization and as such contribute to medica-
tion safety programmes. The PCF might be particularly
useful for older patients, who tend to use more medica-
tions. District nurses and social workers care should be
alerted if the frequency of prescription changes increases
in their patients. Community pharmacists can use the
PCF as a clinical rule to facilitate early identification of
potential drug-related problems. Further research is
needed to determine the predictive value of the PCF in
practice as a clinical rule.
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